These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 7816796)

  • 1. Different topoisomerase II antitumor drugs direct similar specific long-range fragmentation of an amplified c-MYC gene locus in living cells and in high-salt-extracted nuclei.
    Gromova II; Thomsen B; Razin SV
    Proc Natl Acad Sci U S A; 1995 Jan; 92(1):102-6. PubMed ID: 7816796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene.
    Pommier Y; Orr A; Kohn KW; Riou JF
    Cancer Res; 1992 Jun; 52(11):3125-30. PubMed ID: 1317259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo and in vitro stimulation by antitumor drugs of the topoisomerase II-induced cleavage sites in c-myc proto-oncogene.
    Riou JF; Vilarem MJ; Larsen CJ; Multon E; Riou GF
    NCI Monogr; 1987; (4):41-7. PubMed ID: 2819730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
    Giaccone G; Gazdar AF; Beck H; Zunino F; Capranico G
    Cancer Res; 1992 Apr; 52(7):1666-74. PubMed ID: 1312895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo stimulation by antitumor drugs of the topoisomerase II induced cleavage sites in c-myc protooncogene.
    Riou JF; Multon E; Vilarem MJ; Larsen CJ; Riou G
    Biochem Biophys Res Commun; 1986 May; 137(1):154-60. PubMed ID: 3013177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulation of the topoisomerase II induced DNA cleavage sites in the c-myc protooncogene by antitumor drugs is associated with gene expression.
    Riou JF; Lefevre D; Riou G
    Biochemistry; 1989 Nov; 28(23):9104-10. PubMed ID: 2557917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA topoisomerase II isozymes involved in anticancer drug action and resistance.
    Fernandes DJ; Qiu J; Catapano CV
    Adv Enzyme Regul; 1995; 35():265-81. PubMed ID: 7572348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
    Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
    J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression.
    Bertrand R; Sarang M; Jenkin J; Kerrigan D; Pommier Y
    Cancer Res; 1991 Dec; 51(23 Pt 1):6280-5. PubMed ID: 1933888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs.
    Pommier Y; Capranico G; Orr A; Kohn KW
    J Mol Biol; 1991 Dec; 222(4):909-24. PubMed ID: 1662289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility.
    Borgnetto ME; Zunino F; Tinelli S; Kas E; Capranico G
    Cancer Res; 1996 Apr; 56(8):1855-62. PubMed ID: 8620504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417.
    Multon E; Riou JF; LeFevre D; Ahomadegbe JC; Riou G
    Biochem Pharmacol; 1989 Jul; 38(13):2077-86. PubMed ID: 2544183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
    Ritke MK; Roberts D; Allan WP; Raymond J; Bergoltz VV; Yalowich JC
    Br J Cancer; 1994 Apr; 69(4):687-97. PubMed ID: 8142256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
    Spitzner JR; Chung IK; Gootz TD; McGuirk PR; Muller MT
    Mol Pharmacol; 1995 Aug; 48(2):238-49. PubMed ID: 7651357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26.
    Danks MK; Qiu J; Catapano CV; Schmidt CA; Beck WT; Fernandes DJ
    Biochem Pharmacol; 1994 Nov; 48(9):1785-95. PubMed ID: 7980648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine.
    Baguley BC; Leteurtre F; Riou JF; Finlay GJ; Pommier Y
    Eur J Cancer; 1997 Feb; 33(2):272-9. PubMed ID: 9135499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
    Zwelling LA; Chan D; Hinds M; Mayes J; Silberman LE; Blick M
    Cancer Res; 1988 Dec; 48(23):6625-33. PubMed ID: 2846155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.
    Fernandes DJ; Danks MK; Beck WT
    Biochemistry; 1990 May; 29(17):4235-41. PubMed ID: 2163274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.